Media Coverage

“Money Life Market Call” with Buffalo Discovery Fund PM Ken Laudan

December 7, 2020


Buffalo Discovery Fund co-portfolio manager Ken Laudan recently appeared on the “Money Life with Chuck Jaffe” podcast.

During the call, Ken goes in-depth on healthcare investing and provides an overview of his investment methodology. He also covers the current state of the healthcare companies developing the COVID-19 vaccines. Ken also provides thoughts on the following companies:

  • Avantor (NYSE: AVTR)
  • Hologic (NASDAQ: HOLX)
  • Pfizer (NYSE: PFE)
  • AstraZeneca (NASDAQ: AZN)
  • Merck (NYSE: MRK)
  • BioMarin Pharmaceuticals (NASDAQ: BMRN)
  • Centene (NYSE: CNC)
  • Seagen (NASDAQ: SGEN)
  • Bristol-Myers Squibb (NYSE: BMY)

Going from a vaccine discovery point in March to a commercial product in December is stunning; whether that is replicable post COVID I’m dubious, but it’s certainly a positive thing because I just don’t think we’ll have the type of accommodating FDA that we had seen with respect to the vaccine.

~ Ken Laudan, Co-Portfolio Manager, Buffalo Discovery Fund


Ken Laudan
Portfolio Manager
27 Years of Experience
 View full bio

Opinions expressed are those of the author or Funds as of 12/4/20 and are subject to change, are not intended to be a forecast of future events, a guarantee of future results, nor investment advice. References to other mutual funds should not to be considered an offer to buy or sell these securities. A full listing of the Buffalo Discovery Fund portfolio holdings can be found here. Past performance does not guarantee future results. Earnings growth is not representative of the Fund’s future performance. Earnings per share (EPS) is the portion of a company’s profit allocated to each outstanding share of common stock. Earnings per share serves as an indicator of a company’s profitability. The S&P 500 is a capitalization weighted index of 500 large capitalization stocks which is designed to measure broad domestic securities markets. The S&P Biotechnology Select Industry Index represents the biotechnology segment of the S&P Total Market Index, which is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. One cannot invest directly in an index. Free cash flow is a measure of the cash produced by the firm in a given period on behalf of equity holders. The true measure of the value of a firm’s equity is considered to be the present value of all free cash flows.

Sign Up for Automatic Updates

Stay up-to-date with the most recent media coverage and press releases about the Buffalo Funds.


Terms of Use – Email lists are created for use by U.S. investment professionals only and are published strictly for informational purposes. Providing access to the content of these emails does not explicitly or implicitly constitute a solicitation of services or products of the Buffalo Funds, Kornitzer Capital Management, or any of their affiliates. The information contained in the emails is not intended for distribution to, or for use by, investment professionals in a jurisdiction where distribution or purchase is not authorized. The information contained in these emails is not appropriate for use by individual investors. By registering for any of these emails, you agree to Buffalo's terms and conditions and that you are qualified as an institutional investor or otherwise member of a registered broker/dealer, registered investment advisor, or investment consulting firm.